/
Login
ALRAMZAl Ramz Corporation Investment and Development P.J.S.C.
🇦🇪 DFM
1.46
AED
Analysis Scores
Damodaran ?
23/100
ROIC banka/finans için tanımsız — mevduat/prim fonlaması borç değil hammaddedir; değerleme öz-sermaye (P/DD) tabanlı yapılır
Dalio Risk ?
62/100
Piotroski ?
5/9
Neutral
Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Graham ?
AED1.4
Pahalı
Active Metric?
4/4
Confidence?
72%
Valuation
Potential?
-12.3%
DCF Value ?
0.34
Debt Cycle?
Early Expansion
Data
Data ?
66
2026-05-26 → 2026-09-02
Risk Analysis (VaR)
Düşük
65 days
Annual Volatility ?
%11.5
VaR 95% ?
%1.28
daily max loss
VaR 99% ?
%1.77
daily max loss
CVaR 95% ?
%0.14
expected loss (tail)
Max Drawdown ?
%5.8
26.05.2026 → 23.06.2026
Skewness ?
-3.99
Parametrik%1.28
Historik-
Cornish-Fisher%1.54
Return Distribution
Fundamental & Technical Analysis
TRAMA-99 Trend — Near TRAMA
Price (1.46), TRAMA-99 line (1.46) at close levels (%+0.0). Important decision zone — breakout direction will determine the trend.
Price:: 1.46
TRAMA: 1.46
Difference: %+0.0
Profitability
Net Profit Margin
%27.4
Net profit margin %27.4 — very strong. Compared to previous quarter -13.5 point decrease.
ROE – Özkaynak Getirisi (TTM)
%4.7
ROE %4.7 — low return on equity.
EBITDA Margin
%46.2
EBITDA margin %46.2 — operationally very efficient.
Gross Profit Margin
%56.0
Gross profit per revenue %56.0. Strong pricing power.
Free Cash Flow Margin (TTM)
%336.9
TTM Free Cash Flow is %336.9'i. Strong FCF generation — profit quality is high.
Valuation
P/E Ratio
15.0x
Sector: 10.8x
F/K 15.0x — sector median's (10.8x) %39 above. Expensive zone.
P/B Ratio
1.35x
Sector: 2.16x
PD/DD 1.35x — sector median's (2.16x) çok below. Defter değerine göre undervalued.
EV/EBITDA
13.7x
Sector: 8.8x
EV/EBITDA 13.7x — sector median's (8.8x) %54 above. EBITDA’ya göre pahalı.
Indebtedness
Current Ratio
1.39x
Current ratio 1.39x — can comfortably cover short-term debts.
Net Debt / EBITDA
7.3x
Net Borç/EBITDA 7.3x — excessive leverage. Fragile debt profile.
Debt / Equity
1.03x
Borç/Özkaynak 1.03x — moderate financial leverage.
Interest Coverage
3.2x
Interest coverage 3.2x — interest obligations comfortably covered.
Growth
Revenue Growth (YoY)
%+33.7
Revenue YoY %33.7 grew (2026/3) — strong growth. Sector expansion and/or market share increase.
Net Profit Growth (YoY)
%+79.7
Net profit YoY %79.7 increased (2026/3) — extraordinary profit growth.
Score Explanations
Lothien Robustness
51/100
Moderate robustness (51/100). Valuation and risk criteria give mixed signals. Detailed review recommended.
Moderate
Potential
-12.3%
Minus %12.3 expected value (1.28) vs current price comparison. 4/4 valuation models give 'BUY' signal. Model confidence %72.
Components: PE target: 1.03 | P/B target: 2.39 | EV/EBITDA target: 0.95 | DCF target: 0.36
Damodaran Valuation
23/100
Low Damodaran score (23/100). DCF analysis does not support current price. Minusk/sorunlu: ROIC banka/finans için tanımsız — mevduat/prim fonlaması borç değil hammaddedir; değerleme öz-sermaye (P/DD) tabanlı yapılır.
Very Weak
Dalio Risk Analysis
62/100
Moderate debt risk (62/100). Interest coverage ratio 3.2x — acceptable. Borç/EBITDA 7.3x — high debt burden.
Leverage: 50/100 | Debt Service: 67/100 | Quality: 88/100
DCF Discounted Cash Flow
0.34
DCF (0.34) current price %76.9 below — cash flows do not support current price.
Current price: 1.46
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
5/9
Moderate Piotroski (5/9). Some balance sheet criteria met, some missing. Note: Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Neutral
Graham Intrinsic Value
AED1.4
Graham intrinsic value: AED1.4. Pahalı
Expensive
⚖️ Sector Comparison
P/E Ratio
15.0x
vs 10.8x
Sector mediannın %39 above — expensive
P/B Ratio
1.35x
vs 2.16x
Compared to sector %38 cheaper (by book value)
EV/EBITDA
13.7x
vs 8.8x
Compared to sector %54 higher EV/EBITDA
Net Profit Margin (TTM)
%30.5
vs %54.7 EBITDA margin
TTM net profit margin %30.5
Charts
Indicators
BB deviation
?
RSI thresholds
?
ALRAMZ — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.